FBXL18

Across TCGA pan-cancer cohorts, FBXL18 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXL18 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FBXL18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXL18 expression acts as an unfavorable survival marker.

OV, STAD, and PRAD are the cancer types where FBXL18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	IV	0.028	0.759	.002	12	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	All	0.213	0.676	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXL18–OV (OS)

Open the OV breakdown →